Trial Profile
Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
- Indications Hepatitis E
- Focus Adverse reactions
- Sponsors Xiamen Innovax Biotech
- 28 Jun 2019 Results evaluating safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years published in the Vaccine
- 05 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 Apr 2015 New trial record